As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Two important proofreader proteins were discovered by scientists from North Carolina State University and the University of North Carolina at Chapel Hill. The proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
During DNA replication, the nucleotides are a correct match most of the time, but occasionally, about one time in a million, there is a mismatch. However a system exists for detecting and repairing these mismatches, i.e., a pair of proteins known as MutS and MutL. MutS slides along the newly created side of the DNA strand after it’s replicated, proofreading it. When it finds a mismatch, it locks into place at the site of the error and recruits MutL to come and join it. MutL puts a nick in the newly synthesized DNA strand to mark it as defective and signals a different protein to gobble up the portion of the DNA containing the error. Then the nucleotide matching starts over, filling the gap again. The entire process reduces replication errors around a thousand fold, serving as our body’s best defense against genetic mutations and the problems that can arise from them, like cancer.
“Every living thing uses this process for DNA replication and repair, and we know what the components are, but there are some key mechanisms that aren’t well understood,” says Keith Weninger, Ph.D., professor of physics at NC State and co-author of a paper (“MutL traps MutS at a DNA mismatch”) in PNAS describing the research. “For example, when the DNA is repaired, it only happens on the new portion of the DNA strand, and not the older template. And the proteins know which way to move along the strand in order to get rid of the defective portion. There’s communication happening here, but disagreement about how it works.”
Researchers know that the PCNA protein plays an important role in this communication. PCNA sits at the site of a DNA split, and its physical orientation at that site indicates which part of a DNA strand is new (strand discrimination signal). Somehow, MutS and MutL interact with that signal, allowing MutL to nick the strand in the proper place and indicate need for repair. Scientists have three models for this communication: MutS and MutL combine to form a clamp that slides toward PCNA to interact with the signal, marking the area they slide along for deletion; or they make a fold in the DNA and “pull” the PCNA toward them to the same effect; or MutL somehow coats the defective area, signaling for repair that way.
Dr. Weninger, along with co-author Dorothy Erie, Ph.D., from UNC-Chapel Hill, set out to determine the most likely method of communication. Using single molecule fluorescence methods, which allowed the researchers to watch one protein moving on one piece of DNA at a time, they determined that when MutS finds an error, it changes shape in a way that allows MutL to bind with it, holding it in place at the site of the mismatch. MutL then changes its shape to “grab” another MutL, and so on, coating the defective part of the strand and nicking the area that needs repair. In other words, Drs. Weninger, Erie, and their colleagues found that the third model was the correct one.
“This system is essential to keeping the genome stable,” says Dr. Weninger. “We know all the players and the beginning and end of the process, but this work fills in one of the middle steps that were completely unknown and very different from what some have imagined. We also know that mutations in MutS and MutL are associated with very specific cancers. But if we’re going to figure out how defects lead to disease, we first must understand how these proteins normally do their job. This research is another step toward that understanding.”